Health-related quality of life in porphyria cutanea tarda: a cross-sectional registry based study

Table 2 Mann–Whitney U test analysis of SF-12 0–100 scores, biochemical markers and symptom scores between women vs. men and treatment initiated vs. treatment not initiated

	N	Median	Quartiles25–75%	P-valueMann–Whitney	Cohen’s d	Mean	Min–max	SD
SF-12 PCS
Treatment initiated	25	87	64–96	.045*	.50	75	19–96	26
Treatment not initiated	35	71	38–90			61	6–100	30
Bodily pain
Treatment initiated	25	100	75–100	.013*	.59	83	0–100	30
Treatment not initiated	36	75	31–100			64	0–100	34
Social functioning
Women	33	75	38–100	.041*	.59	70	0–100	34
Men	28	100	75–100			87	25–100	23
Biochemical markers
Uroporphyrins^a
Women	33	557	286–941	.022*	.62	625	145–1528	370
Men	28	369	215–531			426	128–1018	263
Symptoms
Symptoms score^b
Women	33	6	3–8	.042*	.79	6	0–15	3
Men	28	3	2–6			4	1–9	2

Mann–Whitney U test was performed for all variables in all groups. Only results associated with a p-value < 0.05 are shown. Groups tested: familial PCT vs. sporadic PCT, low-to-moderate alcohol consumption vs. moderate-to-high alcohol consumption, smoking vs. no smoking
The following SF-12 domains were also tested but no significant differences between groups were identified: MCS, role physical, general health, vitality, role emotional, mental health
^aUroporphyrins: urinary excretion of uroporphyrins in nmol/mmol creatinine
^bSymptoms: numerical score based on number and localization of symptoms (0–25)
* p < .05; ** p < .01

ISSN: 1477-7525